NCT07370909RecruitingPhase 3
Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis
A Multi-center, Randomized, Double Blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of LW402 Tablets in Patients With Moderate-to-severe Atopic Dermatitis.
Source: ClinicalTrials.gov · Last updated 27 Aug 2026
Brief summary (registry, in English)
This Phase 3, double-blind (sponsor-open), multicenter, placebo-controlled study aims to evaluate the efficacy and safety of oral LW402 tablets in patients with moderate to severe atopic dermatitis.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 480 (estimated)
- First submitted
- 19 Jan 2026
- Start date
- 3 Mar 2026
- Primary completion date
- 31 Mar 2028
- Lead sponsor
- Shanghai Longwood Biopharmaceuticals Co., Ltd.
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT07370909
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 480
- From 3 Mar 2026 to the primary completion date, 31 Mar 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Subjects with a documented history of hypersensitivity to Janus kinase (JAK) inhibitors.
- Subjects with current or a history of autoimmune diseases other than atopic dermatitis (AD) (e.g., systemic lupus erythematosus \[SLE\], inflammatory bowel disease \[IBD\], Felty's syndrome, scleroderma, inflammatory myopathy, other connective tissue diseases, overlap syndrome) or other skin conditions that may interfere with AD assessment (e.g., contact dermatitis, psoriasis).
Who the study is looking for
- Subjects voluntarily provided informed consent and agreed to participate in the study.
- Gender: no restrictions; Age: 18 to 75 years inclusive (as of the date of signing the informed consent form).
- At screening, subjects met the Hanifin-Rajka diagnostic criteria for atopic dermatitis (AD) (Appendix 4) and had a documented AD history of ≥1 year prior to screening.
- At screening and baseline visits, subjects were required to have moderate-to-severe atopic dermatitis (AD) with all three of the following criteria satisfied:
- Total AD lesion area ≥ 10% of body surface area (BSA)
- Investigator's Global Assessment (IGA) score ≥ 3
- Eczema Area and Severity Index (EASI) score ≥ 16
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.